{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:35:33Z","timestamp":1792445733204,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs have a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions. Acute kidney injury from ICIs has been well studied; incidence ranges from 1% to 5%, with higher incidence when combination ICI therapies are used. Although the overall reported incidence of ICI-associated glomerulonephritis is less than 1%, vasculitis is the most commonly reported ICI-related glomerulonephritis. Other biopsy findings include thrombotic microangiopathy, focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy with secondary amyloidosis. We report a case in which a woman previously treated with the PD-L1 inhibitor durvalumab for locally advanced non-small cell lung cancer with pre-existing antineutrophil cytoplasmic (anti-PR3) antibody who later developed multi-organ vasculitis after ICI exposure, which was successfully treated with rituximab, with continued cancer remission for 3 years.<\/jats:p>","DOI":"10.3389\/fneph.2023.1168614","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:05:08Z","timestamp":1689926708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Immune checkpoint inhibitor\u2013induced multiorgan vasculitis successfully treated with rituximab"],"prefix":"10.3389","volume":"3","author":[{"given":"Sehrish","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naszrin","family":"Arani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Parvathareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don Lynn","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1927313","article-title":"Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis","volume":"10","author":"Abdelrahim","year":"2021","journal-title":"Oncoimmunology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-Pd1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3892\/mco.2019.1859","article-title":"Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-Non-Small cell lung cancer patients treated with pd-1 immune-check point blockade by nivolumab","volume":"11","author":"Giannicola","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-Pd-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of pd-1\/Pd-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4675","article-title":"Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study","volume":"11","author":"Barth","year":"2022","journal-title":"Cancer Med"},{"key":"B9","volume-title":"Evaluation and managment of suspected immune-mediated nephritis","author":"Abudayyeh","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8(2)","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001287","article-title":"Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab","volume":"8","author":"Lin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and Large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8421479","article-title":"Imbalance of circulatory T follicular helper and T follicular regulatory cells in patients with anca-associated vasculitis","volume":"2019","author":"Xu","year":"2019","journal-title":"Mediators Inflammation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806075105","article-title":"Ctla-4 blockade increases ifngamma-producing Cd4+Icoshi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining Cd8+ T cells that provide the proliferative burst after pd-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37959","article-title":"Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective treg cell function exacerbated by the presence of a suppression-resistant effector cell population","volume":"65","author":"Free","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2019.01.012","article-title":"Recruitment of Cxcr3","volume":"99","author":"Audemard-Verger","year":"2019","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived Cxcl9 and Cxcl10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.40766","article-title":"Dampening of Cd8+ T cell response by b cell depletion therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"N\u00e9el","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B cell depletion or absence does not impede anti-tumor activity of pd-1 inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe anca-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in anca-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12969-022-00750-2","article-title":"Anca-associated vasculitis with cardiac valve vegetations in two teenage males: two case reports and a literature review","volume":"20","author":"Theisen","year":"2022","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2023.1168614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:05:11Z","timestamp":1689926711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2023.1168614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":27,"alternative-id":["10.3389\/fneph.2023.1168614"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2023.1168614","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"article-number":"1168614"}}